Primary Membranous Nephropathy

Clinical journal of the American Society of Nephrology : CJASN - Tập 12 Số 6 - Trang 983-997 - 2017
William G. Couser1
1Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington

Tóm tắt

Membranous nephropathy (MN) is a unique glomerular lesion that is the most common cause of idiopathic nephrotic syndrome in nondiabetic white adults. About 80% of cases are renal limited (primary MN, PMN) and 20% are associated with other systemic diseases or exposures (secondary MN). This review focuses only on PMN. Most cases of PMN have circulating IgG4 autoantibody to the podocyte membrane antigen PLA2R (70%), biopsy evidence PLA2R staining indicating recent immunologic disease activity despite negative serum antibody levels (15%), or serum anti-THSD7A (3%–5%). The remaining 10% without demonstrable anti-PLA2R/THSd7A antibody or antigen likely have PMN probably secondary to a different, still unidentified, anti-podocyte antibody. Considerable clinical and experimental data now suggests these antibodies are pathogenic. Clinically, 80% of patients with PMN present with nephrotic syndrome and 20% with non-nephrotic proteinuria. Untreated, about one third undergo spontaneous remission, especially those with absent or low anti-PLA2R levels, one-third progress to ESRD over 10 years, and the remainder develop nonprogressive CKD. Proteinuria can persist for months after circulating anti-PLA2R/THSD7A antibody is no longer detectable (immunologic remission). All patients with PMN should be treated with supportive care from the time of diagnosis to minimize protein excretion. Patients with elevated anti-PLA2R/THSD7A levels and proteinuria >3.5 g/d at diagnosis, and those who fail to reduce proteinuria to <3.5 g after 6 months of supportive care or have complications of nephrotic syndrome, should be considered for immunosuppressive therapy. Accepted regimens include steroids/cyclophosphamide, calcineurin inhibitors, and B cell depletion. With proper management, only 10% or less will develop ESRD over the subsequent 10 years.

Từ khóa


Tài liệu tham khảo

Cattran, 2017, Membranous nephropathy: Integrating basic science into improved clinical management, Kidney Int, 91, 566, 10.1016/j.kint.2016.09.048

Kumar, 2015, Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy, Nephrology (Carlton), 20, 572, 10.1111/nep.12478

De Vriese, 2016, A proposal for a serology-based approach to membranous nephropathy, J Am Soc Nephrol, 28, 421, 10.1681/ASN.2016070776

Francis, 2016, Membranous nephropathy: A journey from bench to bedside, Am J Kidney Dis, 68, 138, 10.1053/j.ajkd.2016.01.030

Debiec, 2016, Immune response against autoantigen PLA2R is not gambling: Implications for pathophysiology, prognosis and therapy, J Am Soc Nephrol, 27, 1275, 10.1681/ASN.2015101170

Ronco, 2015, Pathophysiological advances in membranous nephropathy: Time for a shift in patient’s care, Lancet, 385, 1983, 10.1016/S0140-6736(15)60731-0

Sinico, 2016, Immunology of membranous nephropathy: From animal models to humans, Clin Exp Immunol, 183, 157, 10.1111/cei.12729

Kerjaschki, 2004, Pathomechanisms and molecular basis of membranous glomerulopathy, Lancet, 364, 1194, 10.1016/S0140-6736(04)17154-7

Debiec, 2002, Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies, N Engl J Med, 346, 2053, 10.1056/NEJMoa012895

Beck, 2009, M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N Engl J Med, 361, 11, 10.1056/NEJMoa0810457

Tomas, 2014, Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy, N Engl J Med, 371, 2277, 10.1056/NEJMoa1409354

Larsen, 2016, THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity, Mod Pathol, 29, 421, 10.1038/modpathol.2016.32

Hoxha, 2016, A mechanism for cancer-associated membranous nephropathy, N Engl J Med, 374, 1995, 10.1056/NEJMc1511702

Timmermans, 2013, Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy, Am J Kidney Dis, 62, 1223, 10.1053/j.ajkd.2013.07.019

Stahl, 2017, THSD7A expression in human cancer, Genes Chromosomes Cancer, 56, 314, 10.1002/gcc.22440

Hoxha, 2017, An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy, J Am Soc Nephrol, 28, 520, 10.1681/ASN.2016010050

Lefaucheur, 2006, Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association, Kidney Int, 70, 1510, 10.1038/sj.ki.5001790

Tomas, 2016, Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy, J Clin Invest, 126, 2519, 10.1172/JCI85265

Larsen, 2013, Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies, Mod Pathol, 26, 709, 10.1038/modpathol.2012.207

Dong, 2016, Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in chinese patients with membranous nephropathy, PLoS One, 11, e0156263, 10.1371/journal.pone.0156263

Beck, 2010, Membranous nephropathy: Recent travels and new roads ahead, Kidney Int, 77, 765, 10.1038/ki.2010.34

Svobodova, 2013, Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy, Nephrol Dial Transplant, 28, 1839, 10.1093/ndt/gfs439

Debiec, 2011, PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy, N Engl J Med, 364, 689, 10.1056/NEJMc1011678

Ryan, 2016, Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis, Kidney Int, 89, 1402, 10.1016/j.kint.2015.12.057

Guerry, 2016, Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy, Kidney Int, 89, 1399, 10.1016/j.kint.2015.11.032

Stanescu, 2011, Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy, N Engl J Med, 364, 616, 10.1056/NEJMoa1009742

Xu, 2016, Long-term exposure to air pollution and increased risk of membranous nephropathy in china, J Am Soc Nephrol, 27, 3739, 10.1681/ASN.2016010093

Ma, 2013, The role of complement in membranous nephropathy, Semin Nephrol, 33, 531, 10.1016/j.semnephrol.2013.08.004

Takano, 2013, Complement-mediated cellular injury, Semin Nephrol, 33, 586, 10.1016/j.semnephrol.2013.08.009

Reddy, 2017, Breaking down the complement system: a review and update on novel therapies, Curr Opin Nephrol Hypertens, 26, 123

Spicer, 2007, Induction of passive Heymann nephritis in complement component 6-deficient PVG rats, J Immunol, 179, 172, 10.4049/jimmunol.179.1.172

Salant, 2013, Genetic variants in membranous nephropathy: Perhaps a perfect storm rather than a straightforward conformeropathy?, J Am Soc Nephrol, 24, 525, 10.1681/ASN.2013020166

Bomback, 2013, Can genetics risk-stratify patients with membranous nephropathy?, J Am Soc Nephrol, 24, 1190, 10.1681/ASN.2013060576

Lv, 2013, Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy, J Am Soc Nephrol, 24, 1323, 10.1681/ASN.2012080771

Seitz-Polski, 2016, Epitope spreading of autoantibody response to PLA2R1 is associates with poor prognosis in membranous nephropathy, J Am Soc Nephrol, 27, 1517, 10.1681/ASN.2014111061

Cui, 2017, MHC Class II risk alleles and amino acid residues in idiopathic membranous nephropathy, J Am Soc Nephrol, 28, 1642, 10.1681/ASN.2016020114

Le, 2017, DRB1*15:01 and HLA-DRB3*02:02 in -related membranous nephropathy, J Am Soc Nephrol, 28, 1642, 10.1681/ASN.2016060644

Kao, 2015, Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy, J Am Soc Nephrol, 26, 291, 10.1681/ASN.2013121315

Fresquet, 2015, Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy, J Am Soc Nephrol, 26, 302, 10.1681/ASN.2014050502

Fogo, 2015, AJKD atlas of renal pathology: Membranous nephropathy, Am J Kidney Dis, 66, e15, 10.1053/j.ajkd.2015.07.006

Barbour, 2013, Short-term complications of membranous nephropathy, Contrib Nephrol, 181, 143, 10.1159/000349976

Ponticelli, 2014, Glomerular diseases: Membranous nephropathy--a modern view, Clin J Am Soc Nephrol, 9, 609, 10.2215/CJN.04160413

Thompson, 2015, Complete and partial remission as surrogate end points in membranous nephropathy, J Am Soc Nephrol, 26, 2930, 10.1681/ASN.2015010091

Hladunewich, 2009, The natural history of the non-nephrotic membranous nephropathy patient, Clin J Am Soc Nephrol, 4, 1417, 10.2215/CJN.01330209

Polanco, 2010, Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy, J Am Soc Nephrol, 21, 697, 10.1681/ASN.2009080861

Hofstra, 2011, Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, 6, 1286, 10.2215/CJN.07210810

Hoxha, 2014, PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system, PLoS One, 9, e110681, 10.1371/journal.pone.0110681

Lee, 2016, Patients with primary membranous nephropathy are at high risk of cardiovascular events, Kidney Int, 89, 1111, 10.1016/j.kint.2015.12.041

Radice, 2016, Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in PMN, Autoimmun Rev, 15, 146, 10.1016/j.autrev.2015.10.004

Kanigicherla, 2013, Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy, Kidney Int, 83, 940, 10.1038/ki.2012.486

Li, 2012, Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study, Thromb Res, 130, 501, 10.1016/j.thromres.2012.04.015

Rankin, 2017, Venous thromboembolism in primary nephrotic syndrome - Is the risk high enough to justify prophylactic anticoagulation?, Nephron, 135, 39, 10.1159/000448628

Lee, 2014, Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy, Kidney Int, 85, 1412, 10.1038/ki.2013.476

Leeaphorn, 2014, Prevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studies, Am J Nephrol, 40, 29, 10.1159/000364782

2012, KDIGO clinical practice guideline for glomerulonephritis, Kidney Int Suppl, 2, 139

Cybulsky, 2014, Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: Management of glomerulonephritis in adults, Am J Kidney Dis, 63, 363, 10.1053/j.ajkd.2013.12.001

Cattran, 2017, Membranous nephropathy: thinking through the therapeutic options, Nephrol Dial Transplant, 32, i22, 10.1093/ndt/gfw404

Tran, 2015, Overview of current and alternative therapies for idiopathic membranous nephropathy, Pharmacotherapy, 35, 396, 10.1002/phar.1575

van de Logt, 2016, Pharmacological treatment of primary membranous nephropathy in 2016, Expert Rev Clin Pharmacol, 16, 1

van den Brand, 2014, Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy, J Am Soc Nephrol, 25, 150, 10.1681/ASN.2013020185

Ramachandran, 2016, Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial, Nephrology (Carlton), 21, 139, 10.1111/nep.12569

Bech, 2014, Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, 9, 1386, 10.2215/CJN.10471013

Dussol, 2008, Mycophenolate mofetil monotherapy in membranous nephropathy: A 1-year randomized controlled trial, Am J Kidney Dis, 52, 699, 10.1053/j.ajkd.2008.04.013

Hofstra, 2010, Alkylating agents in membranous nephropathy: Efficacy proven beyond doubt, Nephrol Dial Transplant, 25, 1760, 10.1093/ndt/gfq017

Khan, 2014, Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy, Clin J Am Soc Nephrol, 9, 1001, 10.2215/CJN.04130414

Howman, 2013, Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial, Lancet, 381, 744, 10.1016/S0140-6736(12)61566-9

Faul, 2008, The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A, Nat Med, 14, 931, 10.1038/nm.1857

Ramachandran, 2016, Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy, Kidney Int, 89, 1401, 10.1016/j.kint.2016.02.022

Ruggenenti, 2015, Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy, J Am Soc Nephrol, 26, 2545, 10.1681/ASN.2014070640

Cravedi, 2014, Rituximab in primary membranous nephropathy: First-line therapy, why not?, Nephron Clin Pract, 128, 261, 10.1159/000368589

Dahan, 2017, Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up, J Am Soc Nephrol, 28, 348, 10.1681/ASN.2016040449

Hamilton, 2016, Rituximab versus the modified Ponticelli regime in the treatment of primary membranous nephropathy: A health economic model, J Am Soc Nephrol, 27, 776a

Ponticelli, 2006, A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy, Am J Kidney Dis, 47, 233, 10.1053/j.ajkd.2005.10.016

van de Logt, 2015, Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: A prospective, open label cohort study, PLoS One, 10, e0142033, 10.1371/journal.pone.0142033

Kittanamongkolchai, 2016, Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: A systematic review and meta-analysis, Clin Kidney J, 9, 387, 10.1093/ckj/sfw045

Cortazar, 2017, Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: A case series, BMC Nephrol, 18, 44, 10.1186/s12882-017-0459-z

Waldman, 2016, Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab, Kidney Int Rep, 1, 73, 10.1016/j.ekir.2016.05.002

Müller-Deile, 2015, A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis, Eur J Clin Invest, 45, 1260, 10.1111/eci.12545

Kattah, 2015, Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy, Am J Transplant, 15, 1349, 10.1111/ajt.13133

Dabade, 2008, Recurrent idiopathic membranous nephropathy after kidney transplantation: A surveillance biopsy study, Am J Transplant, 8, 1318, 10.1111/j.1600-6143.2008.02237.x

Ponticelli, 2014, De novo glomerular diseases after renal transplantation, Clin J Am Soc Nephrol, 9, 1479, 10.2215/CJN.12571213

Filippone, 2016, Membranous nephropathy in the kidney allograft, Clin Transplant, 30, 1394, 10.1111/ctr.12847

Cosio, 2017, Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation, Kidney Int, 91, 304, 10.1016/j.kint.2016.08.030

Gupta, 2016, Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation, Clin Transplant, 30, 461, 10.1111/ctr.12711

Hofstra, 2014, Phospholipase A2 receptor antibodies in membranous nephropathy: Unresolved issues, J Am Soc Nephrol, 25, 1137, 10.1681/ASN.2014010091

Willcocks, 2015, Effect of Belimumab on proteinuria and anti-PLA2R autoantibody in idiopathic membranous nephropathy - 6 months data, Nephrol Dial Transplant, 30, iii32, 10.1093/ndt/gfv149.03

Cattran, 2017, Membranous nephropathy: integrating basic science into improved clinical management, Kidney Int, 91, 566, 10.1016/j.kint.2016.09.048

French, 1992, Clusterin in renal tissue: Preferential localization with the terminal complement complex and immunoglobulin deposits in glomeruli, Clin Exp Immunol, 88, 389, 10.1111/j.1365-2249.1992.tb06459.x

Couser, 2014, The etiology of glomerulonephritis: Roles of infection and autoimmunity, Kidney Int, 86, 905, 10.1038/ki.2014.49

Larsen, 2014, Membranous-like glomerulopathy with masked IgG kappa deposits, Kidney Int, 86, 154, 10.1038/ki.2013.548

Hogan, 2015, Drug-induced glomerular disease: Immune-mediated injury, Clin J Am Soc Nephrol, 10, 1300, 10.2215/CJN.01910215

Medrano, 2015, Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens, Biomarkers, 20, 77, 10.3109/1354750X.2014.993708

Thông tin
Thông tin xuất bản

Clinical journal of the American Society of Nephrology : CJASN

Tập 12 Số 6

983-997

Thông tin tác giả